Evidence map›Paper›PMID 39994710›Full record

SynthesisBMC endocrine disorders2025

The association of selenium exposure with the odds of metabolic syndrome: a dose-response meta-analysis.

Rongrong Yuan, Yu Zhang, Jiakai Han

Abstract readMeta-Analysis
In one paragraph

Synthesis in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rongrong YuanDepartment of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Yu ZhangDepartment of Nephrology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Jiakai HanDepartment of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, 475000, China. hjk2024@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelenium is a key regulator of metabolic homeostasis. It has been proposed that exposure to selenium might be associated with metabolic syndrome (MetS). However, the results are contradictory. This meta-analysis was carried out to analyze the relationships between selenium levels in biological samples and odds of Mets.

methodsWe searched Scopus and PubMed databases up until September 2024 to identify relevant studies. Odds ratio (OR) and 95% confidence interval was used to pool the data using a random effects model.

resultsThe meta-analysis encompassed 18 observational studies involving 21,481 participants. It found that higher selenium exposure was related to an elevated likelihood of MetS (OR = 1.30, 95% CI = 1.12-1.51), even after controlling for covariates, such as smoking, age, alcohol consumption, and physical activity. Heterogeneity was significant among the studies (I² = 88.9%, P = 0.001). While elevated serum selenium levels linked to a higher odds of MetS, no such relationship was observed for selenium in urine or toenails. Subgroup analyses indicated that this association was evident only in females (OR = 2.0, 95% CI = 1.17-1.43) and particularly pronounced in individuals aged ≥ 50 years. A dose-response relationship was identified, showing a 6% increase in MetS odds for each additional 10 µg/L of serum selenium, with the odds rising non-linearly when serum levels surpassed 80 µg/L.

conclusionsThis study suggests that selenium may associated with the odds of MetS, following a dose-response relationship.

Indexed as

Metabolic SyndromeSeleniumDose-Response Relationship, DrugFemaleHumansSeleniumDose-responseMeta-analysisMetabolic syndromeSelenium

Identifiers

PMID39994710
PMCPMC11853193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.